Logo image of RGNX

REGENXBIO INC (RGNX) Stock Fundamental Analysis

NASDAQ:RGNX - US75901B1070 - Common Stock

8.97 USD
-0.04 (-0.44%)
Last: 8/25/2025, 8:00:01 PM
9 USD
+0.03 (+0.33%)
After Hours: 8/25/2025, 8:00:01 PM
Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to RGNX. RGNX was compared to 547 industry peers in the Biotechnology industry. The financial health of RGNX is average, but there are quite some concerns on its profitability. While showing a medium growth rate, RGNX is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

RGNX had negative earnings in the past year.
In the past year RGNX has reported a negative cash flow from operations.
In the past 5 years RGNX reported 4 times negative net income.
RGNX had negative operating cash flow in 4 of the past 5 years.
RGNX Yearly Net Income VS EBIT VS OCF VS FCFRGNX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M -200M

1.2 Ratios

Looking at the Return On Assets, with a value of -30.22%, RGNX is in the better half of the industry, outperforming 66.91% of the companies in the same industry.
RGNX has a Return On Equity (-82.17%) which is in line with its industry peers.
Industry RankSector Rank
ROA -30.22%
ROE -82.17%
ROIC N/A
ROA(3y)-42.76%
ROA(5y)-26.5%
ROE(3y)-75.43%
ROE(5y)-47.81%
ROIC(3y)N/A
ROIC(5y)N/A
RGNX Yearly ROA, ROE, ROICRGNX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20 -40 -60 -80

1.3 Margins

The Gross Margin of RGNX (82.44%) is better than 85.74% of its industry peers.
RGNX's Gross Margin has declined in the last couple of years.
RGNX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 82.44%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-12.45%
GM growth 5Y-4.88%
RGNX Yearly Profit, Operating, Gross MarginsRGNX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K

More info and screens

6

2. Health

2.1 Basic Checks

RGNX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, RGNX has more shares outstanding
RGNX has more shares outstanding than it did 5 years ago.
RGNX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
RGNX Yearly Shares OutstandingRGNX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
RGNX Yearly Total Debt VS Total AssetsRGNX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

RGNX has an Altman-Z score of -1.80. This is a bad value and indicates that RGNX is not financially healthy and even has some risk of bankruptcy.
RGNX has a Altman-Z score (-1.80) which is comparable to the rest of the industry.
There is no outstanding debt for RGNX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.8
ROIC/WACCN/A
WACC9.72%
RGNX Yearly LT Debt VS Equity VS FCFRGNX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M

2.3 Liquidity

RGNX has a Current Ratio of 3.13. This indicates that RGNX is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 3.13, RGNX is not doing good in the industry: 62.52% of the companies in the same industry are doing better.
A Quick Ratio of 3.13 indicates that RGNX has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 3.13, RGNX is in line with its industry, outperforming 40.22% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.13
Quick Ratio 3.13
RGNX Yearly Current Assets VS Current LiabilitesRGNX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

6

3. Growth

3.1 Past

RGNX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 34.10%, which is quite impressive.
The Revenue has grown by 74.98% in the past year. This is a very strong growth!
RGNX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 18.81% yearly.
EPS 1Y (TTM)34.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-31.43%
Revenue 1Y (TTM)74.98%
Revenue growth 3Y-43.83%
Revenue growth 5Y18.81%
Sales Q2Q%-4.2%

3.2 Future

RGNX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.19% yearly.
Based on estimates for the next years, RGNX will show a very strong growth in Revenue. The Revenue will grow by 47.33% on average per year.
EPS Next Y62.53%
EPS Next 2Y18.72%
EPS Next 3Y15.28%
EPS Next 5Y13.19%
Revenue Next Year224.38%
Revenue Next 2Y60.63%
Revenue Next 3Y52.7%
Revenue Next 5Y47.33%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
RGNX Yearly Revenue VS EstimatesRGNX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M 1B
RGNX Yearly EPS VS EstimatesRGNX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 -5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RGNX. In the last year negative earnings were reported.
Also next year RGNX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RGNX Price Earnings VS Forward Price EarningsRGNX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RGNX Per share dataRGNX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

A more expensive valuation may be justified as RGNX's earnings are expected to grow with 15.28% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.72%
EPS Next 3Y15.28%

More info and screens

0

5. Dividend

5.1 Amount

RGNX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

REGENXBIO INC

NASDAQ:RGNX (8/25/2025, 8:00:01 PM)

After market: 9 +0.03 (+0.33%)

8.97

-0.04 (-0.44%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-07 2025-08-07/bmo
Earnings (Next)11-04 2025-11-04/amc
Inst Owners87.98%
Inst Owner Change1.92%
Ins Owners7.21%
Ins Owner Change5.06%
Market Cap453.07M
Analysts84.44
Price Target31.03 (245.93%)
Short Float %11.8%
Short Ratio7.25
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-49.31%
Min EPS beat(2)-75.63%
Max EPS beat(2)-22.99%
EPS beat(4)1
Avg EPS beat(4)-21.8%
Min EPS beat(4)-75.63%
Max EPS beat(4)13.65%
EPS beat(8)3
Avg EPS beat(8)-8.99%
EPS beat(12)4
Avg EPS beat(12)-9.5%
EPS beat(16)5
Avg EPS beat(16)-8.41%
Revenue beat(2)0
Avg Revenue beat(2)-19.97%
Min Revenue beat(2)-25.51%
Max Revenue beat(2)-14.42%
Revenue beat(4)1
Avg Revenue beat(4)-12.95%
Min Revenue beat(4)-25.51%
Max Revenue beat(4)0.57%
Revenue beat(8)2
Avg Revenue beat(8)-14.89%
Revenue beat(12)2
Avg Revenue beat(12)-19.57%
Revenue beat(16)4
Avg Revenue beat(16)-14.02%
PT rev (1m)-4.2%
PT rev (3m)-7.59%
EPS NQ rev (1m)-248.17%
EPS NQ rev (3m)30.91%
EPS NY rev (1m)-2915.08%
EPS NY rev (3m)-200.93%
Revenue NQ rev (1m)-37.04%
Revenue NQ rev (3m)49.15%
Revenue NY rev (1m)-15.65%
Revenue NY rev (3m)-12.88%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.91
P/FCF N/A
P/OCF N/A
P/B 2.12
P/tB 2.12
EV/EBITDA N/A
EPS(TTM)-3.44
EYN/A
EPS(NY)-2.69
Fwd EYN/A
FCF(TTM)-1.8
FCFYN/A
OCF(TTM)-1.74
OCFYN/A
SpS3.08
BVpS4.23
TBVpS4.23
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -30.22%
ROE -82.17%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 82.44%
FCFM N/A
ROA(3y)-42.76%
ROA(5y)-26.5%
ROE(3y)-75.43%
ROE(5y)-47.81%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-12.45%
GM growth 5Y-4.88%
F-Score5
Asset Turnover0.27
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 17.8%
Cap/Sales 1.81%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.13
Quick Ratio 3.13
Altman-Z -1.8
F-Score5
WACC9.72%
ROIC/WACCN/A
Cap/Depr(3y)103.5%
Cap/Depr(5y)301.57%
Cap/Sales(3y)13.73%
Cap/Sales(5y)15.3%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)34.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-31.43%
EPS Next Y62.53%
EPS Next 2Y18.72%
EPS Next 3Y15.28%
EPS Next 5Y13.19%
Revenue 1Y (TTM)74.98%
Revenue growth 3Y-43.83%
Revenue growth 5Y18.81%
Sales Q2Q%-4.2%
Revenue Next Year224.38%
Revenue Next 2Y60.63%
Revenue Next 3Y52.7%
Revenue Next 5Y47.33%
EBIT growth 1Y33.28%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year120.51%
EBIT Next 3Y20.32%
EBIT Next 5Y18.2%
FCF growth 1Y61.55%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y59.69%
OCF growth 3YN/A
OCF growth 5YN/A